NasdaqGS - Delayed Quote USD

Intra-Cellular Therapies, Inc. (ITCI)

Compare
75.76 +2.15 (+2.92%)
At close: October 11 at 4:00 PM EDT
75.76 0.00 (0.00%)
After hours: October 11 at 4:01 PM EDT
Loading Chart for ITCI
DELL
  • Previous Close 73.61
  • Open 73.70
  • Bid 75.73 x 200
  • Ask 75.87 x 100
  • Day's Range 73.70 - 76.18
  • 52 Week Range 45.50 - 84.89
  • Volume 615,896
  • Avg. Volume 568,928
  • Market Cap (intraday) 8.005B
  • Beta (5Y Monthly) 1.00
  • PE Ratio (TTM) --
  • EPS (TTM) -0.86
  • Earnings Date Oct 31, 2024 - Nov 4, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 95.97

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

www.intracellulartherapies.com

610

Full Time Employees

December 31

Fiscal Year Ends

Recent News: ITCI

View More

Research Reports: ITCI

View More

Performance Overview: ITCI

Trailing total returns as of 10/11/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

ITCI
5.78%
S&P 500
21.91%

1-Year Return

ITCI
39.55%
S&P 500
33.43%

3-Year Return

ITCI
99.74%
S&P 500
32.42%

5-Year Return

ITCI
855.36%
S&P 500
97.92%

Compare To: ITCI

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ITCI

View More

Valuation Measures

Annual
As of 10/11/2024
  • Market Cap

    8.01B

  • Enterprise Value

    7.00B

  • Trailing P/E

    --

  • Forward P/E

    114.94

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    13.21

  • Price/Book (mrq)

    6.99

  • Enterprise Value/Revenue

    12.43

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -14.93%

  • Return on Assets (ttm)

    -6.91%

  • Return on Equity (ttm)

    -9.62%

  • Revenue (ttm)

    564.53M

  • Net Income Avi to Common (ttm)

    -84.3M

  • Diluted EPS (ttm)

    -0.86

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.02B

  • Total Debt/Equity (mrq)

    1.60%

  • Levered Free Cash Flow (ttm)

    2.34M

Research Analysis: ITCI

View More

Company Insights: ITCI

People Also Watch